The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity.
Thyroid hormones influence the function of many organs and mediate their diverse actions through two types of thyroid hormone receptors, TRalpha and TRbeta. Little is known about effects of ligands that preferentially interact with the two different TR subtypes. In the current study the comparison of the effects of the novel synthetic TRbeta-selective compound GC-1 with T3 at equimolar doses in hypothyroid mice revealed that GC-1 had better triglyceride-lowering and similar cholesterol-lowering effects than T3. T3, but not GC-1, increased heart rate and elevated messenger RNA levels coding for the I(f) channel (HCN2), a cardiac pacemaker that was decreased in hypothyroid mice. T3 had a larger positive inotropic effect than GC-1. T3, but not GC-1, normalized heart and body weights and messenger RNAs of myosin heavy chain alpha and beta and the sarcoplasmic reticulum adenosine triphosphatase (Serca2). Additional dose-response studies in hypercholesteremic rats confirmed the preferential effect of GC-1 on TRbeta-mediated parameters by showing a much higher potency to influence cholesterol and TSH than heart rate. The preferred accumulation of GC-1 in the liver vs. the heart probably also contributes to its marked lipid-lowering effect vs. the absent effect on heart rate. These data indicate that GC-1 could represent a prototype for new drugs for the treatment of high lipid levels or obesity.
Trost
S U
SU
Department of Medicine, University of California, San Diego 92093-0618, USA.
Swanson
E
E
Gloss
B
B
Wang-Iverson
D B
DB
Zhang
H
H
Volodarsky
T
T
Grover
G J
GJ
Baxter
J D
JD
Chiellini
G
G
Scanlan
T S
TS
Dillmann
W H
WH
D000085:Acetates / Q000493:pharmacokinetics / Q000494:pharmacology*; D000818:Animals; D015152:Blotting, Northern; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006321:Heart / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects; D006937:Hypercholesterolemia / Q000235:genetics; D000960:Hypolipidemic Agents / Q000494:pharmacology; D007037:Hypothyroidism / Q000235:genetics; D008055:Lipids / Q000097:blood*; D008297:Male; D051379:Mice; D009929:Organ Size / Q000187:drug effects; D010636:Phenols / Q000493:pharmacokinetics / Q000494:pharmacology*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D011988:Receptors, Thyroid Hormone / Q000819:agonists*; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology
D000085:Acetates; C413355:GC 1 compound; D000960:Hypolipidemic Agents; D008055:Lipids; D010636:Phenols; D012333:RNA, Messenger; D011988:Receptors, Thyroid Hormone; D014284:Triiodothyronine; D013974:Thyroxine